Intel spent the second half of last week, between June 4 and 5, getting hammered alongside the rest of the chip sector. Then things changed on Monday, June 8. Shares of Intel (INTC) jumped about 13% to roughly $112 in early trading, one of the stock’s sharpest single-day moves of the year, after ...
Intel spent the second half of last week, between June 4 and 5, getting hammered alongside the rest of the chip sector. Then things changed on Monday, June 8. Shares of Intel (INTC) jumped about 13% to roughly $112 in early trading, one of the stock’s sharpest single-day moves of the year, after ...
Defiance Launches MUZ: The First 2X Short ETF for Micron Technology, Inc. Defiance ETFs is proud to announce the launch of the Defiance Daily Target 2X Short MU ETF (Ticker: MUZ), the newest addition to its growing suite of single-stock leveraged and inverse ETFs. MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs is proud to announce the launch of the Defiance Daily Target 2X Short MU ETF (Ti...
Defiance Launches MUZ: The First 2X Short ETF for Micron Technology, Inc. Defiance ETFs is proud to announce the launch of the Defiance Daily Target 2X Short MU ETF (Ticker: MUZ), the newest addition to its growing suite of single-stock leveraged and inverse ETFs. MIAMI, June 09, 2026 (GLOBE NEWSWIRE) -- Defiance ETFs is proud to announce the launch of the Defiance Daily Target 2X Short MU ETF (Ticker: MUZ), the newest addition to its growing suite of single-stock leveraged and inverse ETFs. MUZ
Yields on Taiwan’s five-year government bonds jumped to their highest level since 2008 as tighter banking-system liquidity and growing expectations of higher interest rates weighed on demand for local debt. The yield rose 32bps to 1.71%, the highest since November 2008, as seasonal tax payments drained money from the banking system, leaving lenders with a smaller pool of cash to invest in governme...
Yields on Taiwan’s five-year government bonds jumped to their highest level since 2008 as tighter banking-system liquidity and growing expectations of higher interest rates weighed on demand for local debt. The yield rose 32bps to 1.71%, the highest since November 2008, as seasonal tax payments drained money from the banking system, leaving lenders with a smaller pool of cash to invest in government debt. Underscoring the liquidity crunch, Taiwan’s outstanding negotiable certificates of deposit fell Monday to the lowest level since 2014. The decline points to lenders curbing NCD purchases to preserve funding. That’s adding to expectations that the central bank will keep policy restrictive after consumer inflation exceeded its alert threshold in May. “We currently have a 3Q 2026 rate hike penciled in, as energy prices could pick up again in the coming months if oil flows from the Middle East remain disrupted,” said Lynn Song , chief economist for Greater China at ING Bank NV. Taiwan’s central bank is expected to announce its policy decision on June 18, just after the Federal Reserve’s rate decision. Australia & New Zealand Banking Group Ltd. expects a one-off rate hike in Taiwan in September but sees an earlier move in case of a more hawkish stance from the Fed.
Nokia Oyj (HLSE:NOKIA) has outlined a transformation into an AI focused network infrastructure and digital licensing company. NVIDIA has committed a €1b investment in Nokia, aligned with this AI driven pivot. Institutional investors, including Fidelity, have backed this shift in Nokia’s business model. For investors, the size and nature of NVIDIA’s €1b commitment, alongside backing from Fidelity, ...
Nokia Oyj (HLSE:NOKIA) has outlined a transformation into an AI focused network infrastructure and digital licensing company. NVIDIA has committed a €1b investment in Nokia, aligned with this AI driven pivot. Institutional investors, including Fidelity, have backed this shift in Nokia’s business model. For investors, the size and nature of NVIDIA’s €1b commitment, alongside backing from Fidelity, marks a clear break from Nokia’s image as a traditional telecom equipment supplier. The stock,...
Cibus ( CBUS ) Monday said that Craig Wichner, a board member since November 2025, has been appointed as the company’s CEO. Peter Beetham, who has served as the company’s interim CEO, will continue his role as the company’s president and COO. Wichner is the founder and managing partner of Farmland LP, a U.S. farmland investment management firm with more than $350 million in assets and over 19,000 ...
Cibus ( CBUS ) Monday said that Craig Wichner, a board member since November 2025, has been appointed as the company’s CEO. Peter Beetham, who has served as the company’s interim CEO, will continue his role as the company’s president and COO. Wichner is the founder and managing partner of Farmland LP, a U.S. farmland investment management firm with more than $350 million in assets and over 19,000 acres under management. More on Cibus Cibus, Inc. (CBUS) Q1 2026 Earnings Call Transcript Cibus, Inc. (CBUS) Q4 2025 Earnings Call Transcript Cibus outlines runway into late Q1 2027 while shifting U.S. rice launch to 2029 Cibus stock dips after pricing $15M offering Seeking Alpha’s Quant Rating on Cibus
GlaxoSmithKline headquarters in London on Jan. 17, 2022. Hannah Mckay | Reuters UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, in what would be the British drugmaker's largest acquisition in more than a decade, the Financial Times reported Tuesday. The companies have been in discussions with the aim of finalizing a deal as early as this week,...
GlaxoSmithKline headquarters in London on Jan. 17, 2022. Hannah Mckay | Reuters UK pharmaceutical group GSK is in talks to acquire oncology biotech Nuvalent for more than $9 billion, in what would be the British drugmaker's largest acquisition in more than a decade, the Financial Times reported Tuesday. The companies have been in discussions with the aim of finalizing a deal as early as this week, the FT reported, citing people familiar with the matter. Representatives for GSK and Nuvalent did not respond to CNBC's requests for comment. Both sides have yet to reach a final agreement and the talks could still fall apart over last-minute hurdles, according to the report. A potential deal could value Nuvalent at between $9 billion and $10 billion, representing a premium of roughly 29% to 43% over the biotech company's market capitalization of nearly $7 billion at Monday's close. Stock Chart Icon Stock chart icon GSK Plc The deal would be the second largest acquisition in GSK's history, the FT reported, trailing its 2014 asset swap with Novartis in which it assumed control of the Swiss drugmaker's vaccines division in a transaction valued at $20 billion. It would also mark a notable departure from the company's focus on smaller transactions in recent years. GSK chief executive Luke Miels, who took over the job from longtime boss Emma Walmsley at the start of the year, told investors in February that he would focus on transactions in the £2 billion to £4 billion range that were "hiding in plain sight." Miels has been tasked with overhauling a company that has struggled to allay investor concerns about its drug pipeline . GSK's share price has climbed roughly 29% since Miels' appointment was announced in September . Nuvalent's lead asset, neladalkib — a therapy that targets certain types of lung cancer — is currently undergoing FDA review with a deadline of Nov. 27. The company also has a new drug application for zidesamtinib, for patients with a type of cancer known as R...